Our ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of our innovative peptide technology.
Our focus is on applying our peptide technology across a wide range of indications through independent and partnered development pathways.
We’re looking for passionate, innovative individuals who can help us to deliver our technology to the people who need it most, and we’ve fostered a unique working culture to support this mission.
PepGen attended the BioTrinity conference from the 29th of April to the 1st of May 2019. The company was represented by Damian Marron (Chairman of the Board), Dr Caroline Godfrey (CEO) and Dr Sonia Bracegirdle (CBO) at this event. Alongside meetings with potential investors and partners,…
On the 1st of February 2019, PepGen’s £1.6M Innovate UK grant officially commenced. The company will initially focus on platform validation studies in small and large in vivo models, with project management and intellectual property workpackages running parallel to this experimental work.
Mr Damian Marron was appointment as Chairman of PepGen’s Board of Directors on the 22nd of November 2018. Mr Marron has over 30 years of biotechnology and pharmaceutical industry experience as an accomplished serial biotech Chief Executive Officer and Non-Executive Director with a track record of value creation…
